Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy
Sign Up to like & getrecommendations! Published in 2019 at "Thyroid"
DOI: 10.1089/thy.2018.0555
Abstract: Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers, with a median survival of only three to six months. Standard treatment options and even targeted therapies have so far failed to… read more here.
Keywords: anaplastic thyroid; phagocytosis; cd47; atc cell ... See more keywords
Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines
Sign Up to like & getrecommendations! Published in 2023 at "AntiCancer Research"
DOI: 10.21873/anticanres.16252
Abstract: Background/Aim: The prognosis of anaplastic thyroid carcinoma (ATC) is poor, and there is currently no established treatment to improve its outcome. We previously reported that enhancer of zeste homolog 2 (EZH2) was highly expressed in… read more here.
Keywords: cell lines; atc cell; cell; ezh2 inhibitor ... See more keywords